Skip to main content
Clinical Trials/CTRI/2022/11/047232
CTRI/2022/11/047232
Not yet recruiting
未知

To evaluate the in-vivo efficacy and safety of a skin care formulation in terms improvement in skin radiance, skin brightness, skin smoothness, Skin firmness and reduction in intensity of dark spoton healthy female subject.

VEDISTRY PVT LTD.0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
VEDISTRY PVT LTD.
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
VEDISTRY PVT LTD.

Eligibility Criteria

Inclusion Criteria

  • 1Indian female subjects.
  • 2Healthy subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup)
  • 3Between 18 and 45 years of age.
  • 4Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scarâ?¦.).
  • 5Having wheatish to dark complexion.
  • 6Having dark spot (acne PIH) on face and at least one spot of 3\.5 mm diameter

Exclusion Criteria

  • 1\. For Females: Being pregnant or breastfeeding or having stopped to breastfeed in the past three months
  • 2\. For Male: Shave beard 1day prior before visit
  • 3\. Having refused to give his/her assent by not signing the consent form
  • 4\. Taking part in another study liable to interfere with this study
  • 5\. Being insulin\-dependent diabetic or non insulin\-dependent diabetic with a recent therapy (less than 6 months)
  • 6\. Having acne prone skin.
  • 7\. Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months)
  • 8\. Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products or food products.
  • 9\. Following a chronic medicinal treatment comprising any of the following products: aspirin\-based products, anti\-inflammatories, anti\-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol).
  • 10\. Having cutaneous hypersensitivity.

Outcomes

Primary Outcomes

Not specified

Similar Trials